Global Nontuberculous Mycobacterial Infection Market Forecast 2024-2033: Estimated Market Size And Growth Rate
Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
What is the Expected Growth Rate of the Nontuberculous Mycobacterial Infection Market from 2024 to 2033?
The nontuberculous mycobacterial infection market has seen strong growth, increasing from $13.43 billion in 2023 to $14.25 billion in 2024, reflecting a CAGR of 6.1%. This growth is driven by improved diagnostics, an aging population, increased awareness of cystic fibrosis, and the use of immunosuppressive medications.
The nontuberculous mycobacterial infection market is expected to grow strongly, reaching $18.17 billion by 2028, at a CAGR of 6.3%. This growth is attributed to antimicrobial drug development, increasing awareness, genetic research, and telemedicine. Key trends include personalized treatments, regulatory focus, combination therapies, and digital health tools.
Claim Your Free Sample of the Global Nontuberculous Mycobacterial Infection Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
An increase in chronic obstructive pulmonary disease (COPD) cases is expected to drive growth in the nontuberculous mycobacterial infection market. COPD, characterized by airflow limitations, is linked to greater decline in lung function and higher exacerbation rates when coupled with nontuberculous mycobacterial (NTM) infections. According to The Scottish Public Health Observatory, COPD rates rose between 2021 and 2022, with male rates increasing from 83.2 to 97.6 per 100,000 and female rates from 72.6 to 97.3. Thus, the growing COPD prevalence is boosting the nontuberculous mycobacterial infection market.
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies in the nontuberculous mycobacterial infection market are adopting new approval practices to maintain their position. In June 2021, Paratek Pharmaceuticals Inc., a US-based pharmaceutical company, received approval to expand the use of NUZYRA (omadacycline) for treating community-acquired bacterial pneumonia (CABP) in adults. Further, in July 2022, the FDA granted Fast Track designation to NUZYRA for the treatment of nontuberculous mycobacterial lung disease due to Mycobacterium avium complex (MAC), enhancing treatment options for this condition.
Order Now for Fast Delivery of Your Nontuberculous Mycobacterial Infection Market Report!
North America was the largest region in the business email compromise market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the business email compromise market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The Nontuberculous Mycobacterial Infection Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the nontuberculous mycobacterial infection market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Nontuberculous Mycobacterial Infection Market Include
1. Nontuberculous Mycobacterial Infection Market Executive Summary
2. Nontuberculous Mycobacterial Infection Market Segments
3. Nontuberculous Mycobacterial Infection Market Size And Template Market Growth Rate
4. Key Nontuberculous Mycobacterial Infection Market Trends
5. Major Nontuberculous Mycobacterial Infection Market Drivers
……
25. Key Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market
26. Top Nontuberculous Mycobacterial Infection Companies
27. Nontuberculous Mycobacterial Infection Market Opportunities And Strategies
28. Nontuberculous Mycobacterial Infection Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Tuberculosis Diagnostics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/tuberculosis-diagnostics-global-market-report
Cough And Cold Preparations Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cough-and-cold-preparations-global-market-report
Chronic Cough Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
